{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:31:18Z","timestamp":1792042278099,"version":"4.4.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0191895","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T13:29:05Z","timestamp":1518528545000},"page":"e0191895","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":62,"title":["Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice"],"prefix":"10.1371","volume":"13","author":[{"given":"Ryo","family":"Kawakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nozato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4494-3601","authenticated-orcid":true,"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehisa","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,2,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"AL Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"EM Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"MJ Koren","year":"2012","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"DS Kazi","year":"2016","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"E1256","DOI":"10.1073\/pnas.1322009111","article-title":"Therapeutic vaccine against DPP4 improves glucose metabolism in mice","volume":"111","author":"Z Pang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"PD Hsu","year":"2014","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-2275(20)30123-1","article-title":"A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC","volume":"43","author":"S Usui","year":"2002","journal-title":"J Lipid Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7150\/ijbs.3524","article-title":"An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes","volume":"8","author":"L UZhang","year":"2012","journal-title":"Int J Biol Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid","volume":"15","author":"DH Cribbs","year":"2003","journal-title":"Int Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1073\/pnas.0230620100","article-title":"The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism","volume":"100","author":"M Engel","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines\u2014an approach for long-term LDLc management","volume":"9","author":"G Galabova","year":"2014","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11886-012-0345-z","article-title":"PCSK9 inhibitors: potential in cardiovascular therapeutics","volume":"15","author":"RQ Do","year":"2013","journal-title":"Curr Cardiol Rep"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"DW Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"S Poirier","year":"2008","journal-title":"J Bio Chem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"D Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1074\/jbc.M701634200","article-title":"Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation","volume":"282","author":"TS Fisher","year":"2007","journal-title":"J Biol Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/hmg\/ddl077","article-title":"Effect of mutations in the PCSK9 gene on the cell surface LDL receptors","volume":"15","author":"J Cameron","year":"2006","journal-title":"Hum Mol Genet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/HYPERTENSIONAHA.114.04534","article-title":"Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats","volume":"66","author":"H Koriyama","year":"2015","journal-title":"Hypertension"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.iy.08.040190.001511","article-title":"Lymphokine control of in vivo immunoglobulin isotype selection","volume":"8","author":"FD Finkelman","year":"1990","journal-title":"Annu Rev Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"E Crossey","year":"2015","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"MC McNutt","year":"2009","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"MJ Bottomley","year":"2009","journal-title":"J Biol Chem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"M Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.0703402104","article-title":"The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain","volume":"104","author":"EN Hampton","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2008.10.007","article-title":"Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage","volume":"203","author":"J Cameron","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.tibs.2008.06.005","article-title":"PCSK9 and LDL cholesterol: unravelling the target to design the bullet","volume":"33","author":"P Costet","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-like\/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake","volume":"285","author":"YG Ni","year":"2010","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1126\/science.275.5298.391","article-title":"A mouse model with features of familial combined hyperlipidemia","volume":"275","author":"L Masucci-Magoulas","year":"1997","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbrc.2015.11.064","article-title":"Impact of age and sex on the development of atherosclerosis and expression of the related genes in apoE deficient mice","volume":"469","author":"M Liu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1194\/jlr.M061952","article-title":"PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice","volume":"56","author":"A Roubtsova","year":"2015","journal-title":"J Lipid Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1411543","article-title":"Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E","volume":"258","author":"SH Zhang","year":"1992","journal-title":"Science"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1073\/pnas.91.10.4431","article-title":"The two-receptor model of lipoprotein clearance: tests of the hypothesis in \u201cknockout\u201d mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins","volume":"91","author":"S Ishibashi","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1172\/JCI1847","article-title":"Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100","volume":"101","author":"J Boren","year":"1998","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1039\/b700706j","article-title":"The physiological and molecular regulation of lipoprotein assembly and secretion","volume":"3","author":"DA Blasiole","year":"2007","journal-title":"Mol Biosyst"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.ATV.0000155323.18856.a2","article-title":"Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production","volume":"25","author":"JS Millar","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"40693","DOI":"10.1074\/jbc.M106396200","article-title":"Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor","volume":"276","author":"B Teusink","year":"2001","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/89977","article-title":"Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency","volume":"7","author":"XC Jiang","year":"2001","journal-title":"Nat Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14712590802614041","article-title":"Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects","volume":"9","author":"D. Kanduc","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.2174\/138161209789105135","article-title":"\u201cSelf-nonself\u201d peptides in the design of vaccines","volume":"15","author":"D. Kanduc","year":"2009","journal-title":"Curr Pharm Des"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0191895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T04:20:39Z","timestamp":1660450839000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0191895"}},"subtitle":[],"editor":[{"given":"Maria Cristina","family":"Vinci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,13]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0191895","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,13]]}}}